| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| INCYIncyte Corporation | 20.66B | 105.24 | 701.60 | 14.76% | 24.69% | 25.55% | 1.21% | 0.01 |
| TGTXTG Therapeutics, Inc. | 4.88B | 30.71 | 204.73 | 40.8% | 13.31% | 21.87% | 1.14 | |
| AGIOAgios Pharmaceuticals, Inc. | 1.62B | 27.80 | 2.39 | 36.07% | -8.96% | -31.24% | 0.04 | |
| CLRBCellectar Biosciences, Inc. | 15.48M | 3.65 | -0.09 | -200.99% | 0.03 | |||
| CASICASI Pharmaceuticals, Inc. | 21.37M | 1.04 | -0.41 | -15.77% | -183.93% | -301.8% | 11.96 | |
| VORVor Biopharma Inc. | 308.06M | 14.06 | -0.41 | -94.52% | 0.33 | |||
| FATEFate Therapeutics, Inc. | 121.12M | 1.05 | -0.64 | -78.55% | -21.87% | -66.69% | 0.27 | |
| KPTIKaryopharm Therapeutics Inc. | 121.95M | 6.66 | -0.71 | -0.55% | -87.43% |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 53.88M |
| Revenue Growth % | - | - | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 20K | 31K | 30K | 10K | 0 | 194K | 0 | 0 | 849K | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | -20K | -31K | -30K | -10K | 0 | -194K | 0 | 0 | -849K | 53.88M |
| Gross Margin % | - | - | - | - | - | - | - | - | - | 1% |
| Gross Profit Growth % | 0.16% | -0.55% | 0.03% | 0.67% | 1% | - | 1% | - | - | 64.47% |
| Operating Expenses | 23.86M | 28.37M | 36.08M | 62.88M | 67.48M | 91.7M | 131.26M | 139.87M | 164.96M | 247.08M |
| OpEx % of Revenue | - | - | - | - | - | - | - | - | - | 4.59% |
| Selling, General & Admin | 6.09M | 7.96M | 9.65M | 16.1M | 19.65M | 31.31M | 46.54M | 47.05M | 50.57M | 77.11M |
| SG&A % of Revenue | - | - | - | - | - | - | - | - | - | 1.43% |
| Research & Development | 17.78M | 20.4M | 26.43M | 46.79M | 47.83M | 60.4M | 84.72M | 92.81M | 115.23M | 169.97M |
| R&D % of Revenue | - | - | - | - | - | - | - | - | - | 3.15% |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -849K | 0 |
| Operating Income | -23.86M | -28.37M | -36.08M | -62.88M | -67.48M | -91.9M | -131.26M | -139.87M | -165.8M | -193.19M |
| Operating Margin % | - | - | - | - | - | - | - | - | - | -3.59% |
| Operating Income Growth % | -1.02% | -0.19% | -0.27% | -0.74% | -0.07% | -0.36% | -0.43% | -0.07% | -0.19% | -0.17% |
| EBITDA | -23.84M | -28.34M | -36.05M | -62.87M | -67.47M | -91.7M | -130.7M | -139.11M | -164.96M | -192.35M |
| EBITDA Margin % | - | - | - | - | - | - | - | - | - | -3.57% |
| EBITDA Growth % | -1.02% | -0.19% | -0.27% | -0.74% | -0.07% | -0.36% | -0.43% | -0.06% | -0.19% | -0.17% |
| D&A (Non-Cash Add-back) | 20K | 31K | 30K | 10K | 10K | 194K | 558K | 759K | 849K | 848K |
| EBIT | -23.86M | -28.37M | -36.08M | -62.88M | -67.48M | -89.05M | -130.05M | -135.61M | -151.08M | -170.35M |
| Net Interest Income | 40K | -78K | -137K | 2.2M | 4.09M | 2.22M | 792K | 4.03M | 13.17M | 21.23M |
| Interest Income | 128K | 499K | 751K | 3.17M | 4.67M | 2.8M | 1.21M | 4.25M | 14.72M | 22.85M |
| Interest Expense | 88K | 577K | 888K | 970K | 580K | 578K | 414K | 229K | 1.55M | 1.62M |
| Other Income/Expense | 972K | 807K | 943K | 2.64M | 4.44M | 2.27M | 792K | 4.03M | 13.17M | 21.23M |
| Pretax Income | -22.63M | -27.56M | -35.43M | -60.45M | -63.14M | -89.63M | -130.47M | -135.84M | -152.63M | -171.97M |
| Pretax Margin % | - | - | - | - | - | - | - | - | - | -3.19% |
| Income Tax | -20K | -31K | -30K | 0 | 0 | 0 | 0 | 0 | 0 | 2.02M |
| Effective Tax Rate % | 1% | 1% | 1% | 1% | 1% | 1% | 1% | 1% | 1% | 1.01% |
| Net Income | -22.63M | -27.56M | -35.43M | -60.45M | -63.14M | -89.63M | -130.47M | -135.84M | -152.63M | -173.98M |
| Net Margin % | - | - | - | - | - | - | - | - | - | -3.23% |
| Net Income Growth % | -1.05% | -0.22% | -0.29% | -0.71% | -0.04% | -0.42% | -0.46% | -0.04% | -0.12% | -0.14% |
| Net Income (Continuing) | -22.63M | -27.56M | -35.43M | -60.45M | -63.14M | -89.63M | -130.47M | -135.84M | -152.63M | -173.98M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -2.28 | -1.47 | -1.52 | -1.72 | -1.51 | -1.69 | -1.97 | -2.03 | -2.08 | -2.02 |
| EPS Growth % | 0.15% | 0.36% | -0.03% | -0.13% | 0.12% | -0.12% | -0.17% | -0.03% | -0.02% | 0.03% |
| EPS (Basic) | -2.28 | -1.47 | -1.52 | -1.72 | -1.51 | -1.69 | -1.97 | -2.03 | -2.08 | -2.02 |
| Diluted Shares Outstanding | 9.93M | 18.7M | 23.24M | 35.19M | 41.95M | 53.08M | 66.35M | 66.99M | 73.23M | 86.16M |
| Basic Shares Outstanding | 9.93M | 18.7M | 23.24M | 35.19M | 41.95M | 53.08M | 66.35M | 66.99M | 73.23M | 86.16M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 86.87M | 68.81M | 94.64M | 181.2M | 239.6M | 637.29M | 522.29M | 446.43M | 432.48M | 744.83M |
| Cash & Short-Term Investments | 85.75M | 67.79M | 93.14M | 178.99M | 236.89M | 633.32M | 517.96M | 437.99M | 423.96M | 727.39M |
| Cash Only | 15.44M | 9.72M | 11.43M | 16.12M | 26.14M | 325.49M | 90.67M | 51.8M | 37.32M | 224.46M |
| Short-Term Investments | 70.3M | 58.06M | 81.71M | 162.87M | 210.76M | 307.83M | 427.29M | 386.18M | 386.64M | 502.93M |
| Accounts Receivable | 430K | 295K | 216K | 224K | 30K | 0 | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | - | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 725K | 1.28M | 1.99M | -30K | 0 | 0 | 8.44M | 8.52M | 17.43M |
| Total Non-Current Assets | 390K | 1.01M | 1.21M | 1.18M | 2.37M | 9.92M | 11.76M | 9.88M | 16.45M | 15.33M |
| Property, Plant & Equipment | 71K | 40K | 10K | 0 | 278K | 8.36M | 8.25M | 6.38M | 8.85M | 7.49M |
| Fixed Asset Turnover | - | - | - | - | - | - | - | - | - | 7.20x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 319K | 971K | 1.2M | 1.18M | 2.09M | 1.56M | 3.52M | 3.5M | 7.6M | 7.84M |
| Total Assets | 87.26M | 69.82M | 95.85M | 182.38M | 241.97M | 647.21M | 534.05M | 456.31M | 448.94M | 760.16M |
| Asset Turnover | - | - | - | - | - | - | - | - | - | 0.07x |
| Asset Growth % | 62.32% | -0.2% | 0.37% | 0.9% | 0.33% | 1.67% | -0.17% | -0.15% | -0.02% | 0.69% |
| Total Current Liabilities | 5.05M | 5.45M | 10.03M | 13.62M | 15.56M | 26.02M | 22.45M | 24.06M | 35.26M | 78.71M |
| Accounts Payable | 928K | 638K | 1.25M | 3.94M | 3.53M | 2.75M | 3.24M | 1.53M | 2.3M | 1.47M |
| Days Payables Outstanding | 16.94K | 7.51K | 15.18K | 143.63K | - | 5.18K | - | - | 988.81 | - |
| Short-Term Debt | 0 | 0 | 1.53M | 0 | 250K | 3M | 0 | 0 | 0 | 2.61M |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1000K |
| Other Current Liabilities | 0 | 0 | 0 | -185K | 3.69M | 7.02M | 7.92M | 10.3M | 13.15M | 17.51M |
| Current Ratio | 17.18x | 12.62x | 9.43x | 13.31x | 15.39x | 24.49x | 23.26x | 18.56x | 12.26x | 9.46x |
| Quick Ratio | 17.18x | 12.62x | 9.43x | 13.31x | 15.39x | 24.49x | 23.26x | 18.56x | 12.26x | 9.46x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 101K | 7.49M | 5.96M | 7.78M | 7.63M | 10.28M | 4.99M | 11.97M | 16.4M | 267.81M |
| Long-Term Debt | 0 | 7.32M | 5.57M | 7.5M | 7.25M | 4.25M | 0 | 9.16M | 9.33M | 6.92M |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 5.64M | 4.61M | 2.55M | 6.36M | 5.19M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 101K | 170K | 388K | 279K | 377K | 395K | 375K | 265K | 705K | 1.79M |
| Total Liabilities | 5.16M | 12.95M | 15.99M | 21.39M | 23.19M | 36.31M | 27.44M | 36.03M | 51.66M | 346.52M |
| Total Debt | 0 | 7.32M | 7.1M | 7.5M | 7.75M | 14.98M | 6.88M | 14.02M | 17.2M | 16.59M |
| Net Debt | -15.44M | -2.4M | -4.33M | -8.62M | -18.38M | -310.52M | -83.8M | -37.78M | -20.12M | -207.87M |
| Debt / Equity | - | 0.13x | 0.09x | 0.05x | 0.04x | 0.02x | 0.01x | 0.03x | 0.04x | 0.04x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest Coverage | -271.19x | -49.16x | -40.63x | -64.83x | -116.34x | -158.99x | -317.05x | -610.76x | -107.04x | -119.33x |
| Total Equity | 82.1M | 56.88M | 79.86M | 160.99M | 218.78M | 610.9M | 506.61M | 420.28M | 397.27M | 413.64M |
| Equity Growth % | 24.92% | -0.31% | 0.4% | 1.02% | 0.36% | 1.79% | -0.17% | -0.17% | -0.05% | 0.04% |
| Book Value per Share | 8.27 | 3.04 | 3.44 | 4.57 | 5.22 | 11.51 | 7.64 | 6.27 | 5.43 | 4.80 |
| Total Shareholders' Equity | 82.1M | 56.88M | 79.86M | 160.99M | 218.78M | 610.9M | 506.61M | 420.28M | 397.27M | 413.64M |
| Common Stock | 2K | 2K | 3K | 4K | 5K | 7K | 7K | 7K | 7K | 8K |
| Retained Earnings | -26.3M | -53.86M | -89.29M | -149.74M | -212.88M | -302.5M | -432.97M | -568.81M | -721.44M | -895.42M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -87K | -18K | -49K | -131K | 331K | 46K | -1.79M | -8.03M | -1.27M | 764K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -17.93M | -25.35M | -28.44M | -48.66M | -54.76M | -69.83M | -104.55M | -110.06M | -124.82M | 134.32M |
| Operating CF Margin % | - | - | - | - | - | - | - | - | - | 2.49% |
| Operating CF Growth % | -7036.69% | -0.41% | -0.12% | -0.71% | -0.13% | -0.28% | -0.5% | -0.05% | -0.13% | 2.08% |
| Net Income | -22.63M | -27.56M | -35.43M | -60.45M | -63.14M | -89.63M | -130.47M | -135.84M | -152.63M | -173.98M |
| Depreciation & Amortization | 20K | 31K | 30K | 10K | 0 | 194K | 558K | 759K | 849K | 848K |
| Stock-Based Compensation | 2.26M | 2.09M | 4.54M | 8.65M | 9.41M | 12.81M | 23.58M | 26.32M | 28.08M | 33.9M |
| Deferred Taxes | 439K | 129K | -260K | -1.44M | 0 | 0 | 4.6M | 0 | 0 | 0 |
| Other Non-Cash Items | 579K | 42K | 118K | 184K | -1.1M | 410K | 399K | 1.68M | -8.94M | -12.62M |
| Working Capital Changes | 1.4M | -80K | 2.56M | 4.38M | 74K | 6.38M | -3.22M | -2.98M | 7.82M | 286.17M |
| Change in Receivables | -400K | 135K | 79K | -8K | 210K | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 153K | -199K | -750K | -443K | -856K | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 2.81M | 471K | 3.61M | 5.1M | 856K | 5.68M | -2.52M | -802K | 10.33M | 15.2M |
| Cash from Investing | -70.63M | 12.18M | -23.42M | -79.3M | -46.33M | -99.94M | -126.83M | 32.63M | 15.56M | -101.59M |
| Capital Expenditures | -64K | 0 | 0 | 0 | 0 | -2.17M | -1.15M | -626K | -168K | -472K |
| CapEx % of Revenue | - | - | - | - | - | - | - | - | - | 0.01% |
| Acquisitions | - | - | - | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | -70.56K | 12.18K | -23.42K | -79.3K | 0 | -97.77K | -125.69K | 33.25K | 0 | 0 |
| Cash from Financing | 102.87M | 7.45M | 53.57M | 132.64M | 111.1M | 469.33M | -3.44M | 38.56M | 94.78M | 154.42M |
| Debt Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - | - | - | - |
| Other Financing | 0 | 0 | 53.57M | 1.09M | 2.94M | 10.25M | -611K | 3.84M | 1.21M | 8.6M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | -17.99M | -25.35M | -28.44M | -48.66M | -54.76M | -72M | -105.7M | -110.69M | -124.99M | 133.84M |
| FCF Margin % | - | - | - | - | - | - | - | - | - | 2.48% |
| FCF Growth % | -6836.32% | -0.41% | -0.12% | -0.71% | -0.13% | -0.31% | -0.47% | -0.05% | -0.13% | 2.07% |
| FCF per Share | -1.81 | -1.36 | -1.22 | -1.38 | -1.31 | -1.36 | -1.59 | -1.65 | -1.71 | 1.55 |
| FCF Conversion (FCF/Net Income) | 0.79x | 0.92x | 0.80x | 0.80x | 0.87x | 0.78x | 0.80x | 0.81x | 0.82x | -0.77x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Metric | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -57.52% | -39.66% | -51.83% | -50.19% | -33.25% | -21.6% | -23.35% | -29.31% | -37.34% | -42.91% |
| Return on Invested Capital (ROIC) | -55.39% | -35.13% | -41.63% | -41.39% | -28.69% | -27.53% | -27.22% | -26.05% | -32.74% | -49.71% |
| Gross Margin | - | - | - | - | - | - | - | - | - | 100% |
| Net Margin | - | - | - | - | - | - | - | - | - | -322.89% |
| Debt / Equity | - | 0.13x | 0.09x | 0.05x | 0.04x | 0.02x | 0.01x | 0.03x | 0.04x | 0.04x |
| Interest Coverage | -271.19x | -49.16x | -40.63x | -64.83x | -116.34x | -158.99x | -317.05x | -610.76x | -107.04x | -119.33x |
| FCF Conversion | 0.79x | 0.92x | 0.80x | 0.80x | 0.87x | 0.78x | 0.80x | 0.81x | 0.82x | -0.77x |
Kura Oncology, Inc. (KURA) reported $104.0M in revenue for fiscal year 2024.
Kura Oncology, Inc. (KURA) grew revenue by 0.0% over the past year. Growth has been modest.
Kura Oncology, Inc. (KURA) reported a net loss of $216.9M for fiscal year 2024.
Kura Oncology, Inc. (KURA) has a return on equity (ROE) of -42.9%. Negative ROE indicates the company is unprofitable.
Kura Oncology, Inc. (KURA) generated $83.1M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.